Form DEFA14A Immunome Inc.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
|
|
|||
|
Check the appropriate box:
|
|||
|
☐
|
|
|
Preliminary Proxy Statement
|
|
☐
|
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
|
|
Definitive Proxy Statement
|
|
☒
|
|
|
Definitive Additional Materials
|
|
☐
|
|
|
Soliciting Material under § 240.14a-12
|
|
|
|
|
|
|
|
|||
|
Immunome, Inc.
|
|||
|
(Name of Registrant as Specified in Its Charter)
|
|||
|
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
|
|||
|
|
|||
Payment of Filing Fee (Check all boxes that apply):
|
|
|
|
|
| ☒ |
|
|
No fee required
|
|
☐
|
|
|
Fee paid previously with preliminary materials
|
| ☐ |
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
|
|
|
|
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Immunome doses first patient in Phase 1 trial of IM-1617 cancer drug
- Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
- Oshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
